Rethinking the multiple roles of B cells in organ transplantation

Current Opinion in Organ Transplantation

Volumn 18, Issue 1, 2013, Pages 13-21

  Coelho, Verônica ^a,b   Saitovitch, David ^b,c   Kalil, Jorge ^a,b   Silva, Hernandez Moura ^b,d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute of Science and Technology (INCT)   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alloantibodies; autoantibodies; B cells; regulatory B cells; reshaping the B cell compartment; transplantation tolerance

Indexed keywords

ALEMTUZUMAB; ALPHA TUBULIN; ANGIOTENSIN RECEPTOR; BORTEZOMIB; CORTICOSTEROID; DACLIZUMAB; GAMMA INTERFERON; IMMUNOGLOBULIN G3; INTERLEUKIN 10; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEOLIN; RAPAMYCIN; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VIMENTIN;

ALLERGIC ENCEPHALOMYELITIS; ALLOIMMUNITY; ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL POPULATION; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE; DENDRITIC CELL; GRAFT FAILURE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOCYTE FUNCTION; MEMORY CELL; ORGAN TRANSPLANTATION; PHENOTYPE; PLASMAPHERESIS; PRE B LYMPHOCYTE; REGULATORY T LYMPHOCYTE; REVIEW; SKIN TRANSPLANTATION; TH17 CELL; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; B-LYMPHOCYTES, REGULATORY; CELL MOVEMENT; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PHENOTYPE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 84872976616     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835c8043     Document Type: Review

References (114)

1. Kweon MN, Fujihashi K, VanCott JL, et al. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice. J Immunol 1998; 160:1687-1693.
2. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation-friend or foe? Immunity 2001; 14:357-368.
3. + T cell lineage differentiation. Immunity 2009; 30:646-655.
4. Olofsson PS, Rosas-Ballina M, Levine YA, Tracey KJ. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol Rev 2012; 248:188-204.
5. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1:97-102.
6. + regulatory T cells with indirect allospe-cificity and short term immunosuppression. Transpl Immunol 2009; 21: 203-209.
7. + Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Investig 2008; 118:3619-3628.
8. Otto C, Rohde AC, Timmermann W, et al. Acceptance of small bowel allografts by indirect allorecognition of donor class II MHC allopeptides. Transplant Proc 2001; 33:431-432.
9. Gasser M, Lenhard SM, Otto C, et al. Modulation of the immune response with major histocompatability class II peptides via the indirect pathway of allorecognition after kidney and small bowel transplantation. Transplant Proc 2002; 34:2244-2245.
10. + indirect alloreactive T cells from renal transplant patients suppress both the direct and indirect pathways of allorecognition. Scand J Immunol 2007; 66:352-361.
11. + T cell immunity. Nat Rev Immunol 2010; 10:236-247.
12. Swain SL, Dutton RW. Consequences of the direct interaction of helper T cells with B cells presenting antigen. Immunol Rev 1987; 99:263-280.
13. Pierce SK, Morris JF, Grusby MJ, et al. Antigen-presenting function of B lymphocytes. Immunol Rev 1988; 106:149-180.
14. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006; 176:705-710.
15. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production byeffectorB andT cells. Nat Immunol 2000; 1:475-482.
16. Harris DP, Goodrich S, Gerth AJ, et al. Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 2005; 174:6781-6790.
17. Crawford A, Macleod M, Schumacher T, et al. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 2006; 176:3498-3506.
18. Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol 2000; 165:5558-5565.
19. Hashimoto Y, Montecino-Rodriguez E, Leathers H, et al. B-cell development in the thymus is limited by inhibitory signals from the thymic microenviron-ment. Blood 2002; 100:3504-3511.
20. Wolf SD, Dittel BN, Hardardottir F, Janeway CA Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184:2271-2278.
21. + T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007; 178:3447-3456.
22. Fillatreau S, Sweenie CH, McGeachy MJ, et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3:944-950.
23. Sun Q, Liu Z, Yin G, et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79:1759-1762.
24. Sun Q, Liu Z, Chen J, et al. Circulating antiendothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin J Am Soc Nephrol 2008; 3:1479-1486.
25. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132-2143.
26. Stastny P, Ring S, Lu C, et al. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009; 70:600-604.
27. Graff RJ, Xiao H, Schnitzler MA, et al. The role of positive flow cytometry crossmatch in late renal allograft loss. Hum Immunol 2009; 70:502-505.
28. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating antiendothelial cell antibodies rather than preexisting antibodies is associated with posttransplant allograft rejection. Kidney Int 2011; 79:655-662.
29. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157-1167.
30. Kokko KE, Colvin RB. Below the waterline-the danger of de novo donor-specific HLA antibodies. Am J Transplant 2012; 12:1077-1078.
31. Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006; 82 (1 Suppl.):S33-S35.
32. Kaneku H, O'Leary JG, Taniguchi M, et al. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18:984-992.
33. Thiyagarajan UM, Bagul A, Frost J, et al. Role of human leukocyte antigen, donor-specific antibodies, and their impact in renal transplantation. Transplant Proc 2012; 44:1231-1235.
34. Portugal K, Dozmorov I, Sidorov I, et al. Renal transplant patients show variations in their self-reactive repertoires: a serial study. Int Immunol 2001; 13:747-755.
35. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78:503-513.
36. Hagedorn PH, Burton CM, Carlsen J, et al. Chronic rejection of a lung transplant is characterized by a profile of specific autoantibodies. Immunology 2010; 130:427-435.
37. Wilkes DS. Autoantibody formation in human and rat studies of chronic rejection and primary graft dysfunction. Semin Immunol 2012; 24:131-135.
38. Nath DS, Tiriveedhi V, Basha HI, et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011; 91:1036-1043.
39. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008; 180:4487-4494.
40. Azimzadeh AM, Pfeiffer S, Wu GS, et al. Humoral immunity to vimentin is associated with cardiac allograft injury in nonhuman primates. Am J Transplant 2005; 5:2349-2359.
41. Jonker M, Danskine A, Haanstra K, et al. The autoimmune response to vimentin after renal transplantation in nonhuman primates is immunosuppres-sion dependent. Transplantation 2005; 80:385-393.
42. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
43. Qin Z, Lavingia B, Zou Y, Stastny P. Antibodies against nucleolin in recipients of organ transplants. Transplantation 2011; 92:829-835.
44. Iwata T, Philipovskiy A, Fisher AJ, et al. Antitype V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181: 5738-5747.
45. Porcheray F, DeVito J, Yeap BY, et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 2010; 89:1239-1246.
46. Quintana FJ, Merbl Y, Sahar E, et al. Antigen-chip technology for accessing global information about the state of the body. Lupus 2006; 15:428-430.
47. Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Investig 2007; 117:712-718.
48. Cohen IR. Real and artificial immune systems: computing the state of the body. Nat Rev Immunol 2007; 7:569-574.
49. Cohen IR. Biomarkers, self-antigens and the immunological homunculus. J Autoimmun 2007; 29:246-249.
50. Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in graft rejection and tolerance. Transplant Rev (Orlando) 2010; 24:67-78.
51. Thibault-Espitia A, Foucher Y, Danger R, et al. BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transplant 2012; 12:2754-2762.
52. Thaunat O. Pathophysiologic significance of B-cell clusters in chronically rejected grafts. Transplantation 2011; 92:121-126.
53. Thaunat O, Patey N, Caligiuri G, et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol 2010; 185:717-728.
54. Thaunat O, Graff-Dubois S, Fabien N, et al. A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int 2012; 81:207-219.
55. Redfield RR 3rd, Rodriguez E, Parsons R, et al. Essential role for B cells in transplantation tolerance. Curr Opin Immunol 2011; 23:685-691.
56. Newell KA, Phippard D, Turka LA. Regulatory cells and cell signatures in clinical transplantation tolerance. Curr Opin Immunol 2011; 23:655-659.
57. Kwun J, Bulut P, Kim E, et al. The role of B cells in solid organ transplantation. Semin Immunol 2012; 24:96-108.
58. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant 2011; 11:1359-1367.
59. Chong AS, Sciammas R. Matchmaking the B-cell signature of tolerance to regulatory B cells. Am J Transplant 2011; 11:2555-2560.
60. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006; 108:2485-2492.
61. Noorchashm H, Reed AJ, Rostami SY, et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006; 177:7715-7722.
62. DiLillo DJ, Griffiths R, Seshan SV, et al. B lymphocytes differentially influence acute and chronic allograft rejection in mice. J Immunol 2011; 186:2643-2654.
63. Mauri C, Blair PA. Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 2010; 6:636-643.
64. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012; 30:221-241.
65. Mizoguchi A, Mizoguchi E, Takedatsu H, et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16:219-230.
66. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197:489-501.
67. + phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28:639-650.
68. Iwata Y, Matsushita T, Horikawa M, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117:530-541.
69. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32:129-140.
70. Le Texier L, Thebault P, Lavault A, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011; 11:429-438.
71. Ding Q, Yeung M, Camirand G, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Investig 2011; 121:3645-3656.
72. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998; 10:518-524.
73. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 2006; 212: 301-313.
74. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104:15448-15453.
75. Ashton-Chess J, Giral M, Soulillou JP, Brouard S. Using biomarkers of tolerance and rejection to identify high-and low-risk patients following kidney transplantation. Transplantation 2009; 87 (9 Suppl.):S95-S99.
76. Moraes-Vieira PM, Takenaka MC, Silva HM, et al. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol 2012; 142:117-126.
77. + T cells in kidney operational tolerance transplanted individuals. Hum Immunol 2010; 71:442-450.
78. Newell KA, Asare A, Kirk AD, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120:1836-1847.
79. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.
80. Silva HM, Takenaka MC, Moraes-Vieira PM, et al. Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol Med 2012; 18:733-743.
81. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs pre dominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
82. Danger R, Pallier A, Giral M, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012; 23:597-606.
83. Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of rituximab in organ transplantation. Transpl Int 2006; 19:621-628.
84. Venetz JP, Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007; 16:625-633.
85. Fehr T, Rusi B, Fischer A, et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87:1837-1841.
86. Uckun FM. Regulation of human B-cell ontogeny. Blood 1990; 76:1908-1923.
87. Kamburova EG, Koenen HJ, Boon L, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012; 12:341-350.
88. Tyden G, Genberg H, Tollemar J, et al. A randomized, double-blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87:1325-1329.
89. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360:2683-2685.
90. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87:1555-1561.
91. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89:277-284.
92. Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 2012; 81:1067-1074.
93. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107:4907-4916.
94. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67:1783-1792.
95. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86:1754-1761.
96. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific antihuman leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012; 93:319-324.
97. Hale G, Swirsky DM, Hayhoe FG, Waldmann H. Effects of monoclonal antilymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983; 1:321-334.
98. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35:118-127.
99. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzu-mab. Blood 2002; 100:1715-1720.
100. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702.
101. Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclos-porine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-1616.
102. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909-1919.
103. Heidt S, Hester J, Shankar S, et al. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells. Am J Transplant 2012; 12:1784-1792.
104. Cherukuri A, Salama AD, Carter C, et al. An analysis of lymphocyte pheno-type after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. Am J Transplant 2012; 12:919-931.
105. Bloom D, Chang Z, Pauly K, et al. BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant 2009; 9:1835-1845.
106. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21:231-264.
107. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009; 9:491-502.
108. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2:465-475.
109. LaMattina JC, Mezrich JD, Hofmann RM, et al. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int 2012; 25:518-526.
110. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B. Drugs R D 2010; 10:55-65.
111. Parsons RF, Yu M, Vivek K, et al. Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation 2012; 93:676-685.
112. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-8347.
113. + T cells in BAFF-transgenic mice suppress T cell effector responses. J Immunol 2009; 182:793-801.
114. Riewaldt J, Duber S, Boernert M, et al. Severe developmental B lymphopoietic defects in Foxp3-deficient mice are refractory to adoptive regulatory T cell therapy. Front Immunol 2012; 3:141.